JERSEY CITY, N.J. , Aug. 9, 2022 /PRNewswire/ -- InsightAce Analytic Pvt. Ltd. announces the release of market assessment report on "Global Peptide–drug Conjugates (PDCs) Market By Product (Lutetium Lu 177 dotatate, Melflufen, ANG1005, BT1718, CBX-12, and Other Pipeline Products) By Indication (Relapsed/Refractory Multiple Myeloma, Neuroendocrine Tumors (NETs), Gastric Cancers, Acromegaly, Ophthalmology, and Other Cancer Indications. )– Technology Trends, Industry Competition Analysis, Revenue and Forecast Till 2030"
According to the latest research by InsightAce Analytic, the global peptide–drug conjugates (PDCs) market is expected to record a promising CAGR of 13.7% during the period of 2022-2030. By region, North America dominates the global peptide–drug conjugates (PDCs) market with the largest share.
Request for Sample Pages: https://www.insightaceanalytic.com/report/global-peptidedrug-conjugates-pdcs-market/1351
The peptide drug conjugates are targeted therapeutic drugs, targeting the tumor cell to release the cytotoxin. The swelling investments by key players to develop promising therapies are anticipated to fuel the market growth over the forecast period. The emergence of Peptide–Drug Conjugates (PDCs) therapy for patients suffering from different types of cancers is believed to create a number of clinical opportunities during the forecast period. PDC uses a peptide chain of about ten amino acids to target tumour cells, and its molecular weight is smaller than ADC, which can be rapidly enriched to tumour sites. At the same time, drug molecules in blood can be cleared quickly with a short half-life, helping to reduce toxic side effects caused by off-targeting.
Peptide–drug conjugates (PDCs) are a novel targeted therapy that exhibits enhanced tumour penetrance and selectivity. Peptide–drug conjugates (PDCs) are a promising field of study, as evidenced by the two PDCs now available on the market. In addition, PDCs with the proper design and focus is expected to affect the targeted therapeutic market by delivering safer medications. The increasing number of pharmaceutical drug innovations is expected to fuel the growth of peptide–drug conjugates (PDCs) market in the near future. Also, in the coming days, there will be rapid approval of peptide drug conjugates in treating cancers due to the robust clinical pipeline of drugs. Despite these, the peptide drug conjugates have several limitations which hinder the growth of the PDCs market. Major driving factors of peptide–drug conjugates (PDCs) market are the increasing need for therapeutic drugs, high prevalence of cancer diseases, rising number of clinical trials, and increasing investments by key players to develop promising therapies. Furthermore, advanced medical technologies, growth in the population, and a growing number of health-conscious people enhance the market growth.
However, the high-cost treatments, complex procedures, and lack of strict government laws limit the market growth. Moreover, the COVID-19 pandemic has negatively impacted this market due to the lockdown situation. In addition, the pipeline product approval process may hamper the product market and production as a lot of clinical trials are going on today. On the other hand, FDA has approved very few pipeline products regarding peptide drug conjugates in the last five years, which will impact the market in the forecasting period.
At the regional level, North America , followed by the Europe region, is expected to hold the highest share of this market over the forecast period due to the high prevalence of cancer, fast adoption of advanced technologies, rising awareness about therapeutic drugs, and increasing government investments and funding in R&D of therapeutic medications. In addition, the Asia-Pacific region is expected to show significant market growth in the future owing to the advancement of modern technologies and the rising prevalence of cancer.
The key players involved in peptide–drug conjugates (PDCs) industry are Novartis AG, AstraZeneca, Bicycle Therapeutics, Cybrexa Therapeutics, Esperance Pharmaceuticals, Oncopeptides AB, Pepgen Corporation, Soricimed Biopharma, Theratechnologies, Pfizer Inc, Validus Pharmaceuticals LLC, Antisense Therapeutics, Midatech Pharma PLC, Ipsen Pharma, Chiasma, Inc., Peptron, Inc., CRINETICS PHARMACEUTICALS, Dauntless Pharmaceuticals, Camurus AB, Teva Pharmaceuticals Inc., Pharmaspur, Aspire Pharmaceuticals, Ionis Pharmaceuticals Inc, Midatech Pharma Plc, and Other Prominent Players. This field's leading players use strategies like novel therapy innovations, partnerships, collaborations, mergers, and agreements.
Key developments in the market
In Dec 2021 , A strategic partnership agreement was signed between Coherent Biopharma and WuXi STA. In order to speed up the development of its current and future drug candidates (small molecules, peptides, oligonucleotides, complex chemical conjugates, etc.), from API to drug product, the company will offer Coherent Biopharma integrated CMC services.
In Oct 2021 , Oncopeptides AB announced the withdrawal of Pepaxto® (INN melphalan flufenamide) from the US market. Oncopeptides will collaborate with the FDA to keep the drug available for patients who are currently receiving Pepaxto treatment.
In July 2020 , AstraZeneca and Daiichi Sankyo formed a new $6 billion global ADC alliance to co-develop and commercialise DS-1062, a TROP2 directed DXd antibody-drug conjugate in Phase I for non-small cell lung cancer and breast cancer. The businesses will share development and commercialization costs as well as profits from DS-1062 worldwide, except for Japan .
In June 2019 , Novartis AG and PeptiDream Inc. signed a new Peptide Drug Conjugate "PDC" collaboration agreement to initiate macrocyclic peptide discovery, which will be used to address therapeutic and diagnostic applications.
Curious about Details @ https://www.insightaceanalytic.com/report/global-peptidedrug-conjugates-pdcs-market/1351
Global peptide–drug Conjugates (PDCs) Market, by Product, 2022-2030 (Value US$ Mn)
Global peptide–drug Conjugates (PDCs) Market, by Indication, 2022-2030 (Value US$ Mn)
Global peptide–drug Conjugates (PDCs) Market, by Region, 2022-2030 (Value US$ Mn)
North America Peptide–drug Conjugates (PDCs) Market, by Country, 2022-2030 (Value US$ Mn)
Europe Peptide–drug Conjugates (PDCs) Market, by Country, 2022-2030 (Value US$ Mn)
Asia Pacific Peptide–drug Conjugates (PDCs) Market, by Country, 2022-2030 (Value US$ Mn)
Latin America Peptide–drug Conjugates (PDCs) Market, by Country, 2022-2030 (Value US$ Mn)
Middle East & Africa Peptide–drug Conjugates (PDCs) Market, by Country, 2022-2030 (Value US$ Mn)
Rest of Middle East & Africa
For More Customization @ https://www.insightaceanalytic.com/customisation/1351
Why should buy this report:
To receive a comprehensive analysis of the prospects for global peptide–drug conjugates (PDCs) products
To receive industry overview and future clinical trial/pipeline trends of global peptide–drug conjugates (PDCs) market
To analyse the peptide–drug conjugates (PDCs) market drivers and challenges
To get information on peptide–drug conjugates (PDCs) market size value (US$ Mn) forecast till 2030
To get information on major Investments, Mergers & Acquisition in global peptide–drug conjugates (PDCs) market industry
Other Related Reports Published by InsightAce Analytic:
Global Polymer Drug Conjugates Market
Global Neoantigen Peptides Manufacturing Market
Global Antibody Drug Conjugates (Adcs) – Linker And Conjugation Technologies Market
Global Peptide CDMO (Pharmaceutical) Market
InsightAce Analytic is a market research and consulting firm that enables clients to make strategic decisions. Our qualitative and quantitative market intelligence solutions inform the need for market and competitive intelligence to expand businesses. We help clients gain competitive advantage by identifying untapped markets, exploring new and competing technologies, segmenting potential markets and repositioning products. Our expertise is in providing syndicated and custom market intelligence reports with an in-depth analysis with key market insights in a timely and cost-effective manner.
Contact Us: InsightAce Analytic Pvt. Ltd. Tel.: +1 551 226 6109 Email: info@insightaceanalytic.com Site Visit: www.insightaceanalytic.com Follow Us on LinkedIn @ bit.ly/2tBXsgS Follow Us On Facebook @ bit.ly/2H9jnDZ
Logo: https://mma.prnewswire.com/media/1729637/InsightAce_Analytic_Logo.jpg
View original content:https://www.prnewswire.com/news-releases/peptidedrug-conjugates-pdcs-market-future-pipelineclinical-trial-analysis-and-revenue-forecast-snapshot---exclusive-report-by-insightace-analytic-301602539.html
SOURCE InsightAce Analytic Pvt. Ltd.
New drugs from Eli Lilly and Novo Nordisk have shown striking results in studies. If insurers step up to back them, the drugs—and the stocks—could take off.
Vaxxinity missed out on Operation Warp Speed and the first round of COVID-19 vaccines, but CEO Mei Mei Hu is focused on the second generation and ongoing global needs.
Alibaba Group Holding Limited (NYSE: BABA) and Tencent Holding Ltd (OTC: TCEHY) submitted the algorithm details of some of their products to China's top internet watchdog, Reuters reports. The submission was a part of China's sweeping crackdown on the sector. The internet platforms faced flak for abusing algorithms to invade user privacy and manipulate their choices. The Cyberspace Administration of China (CAC) published a list of 30 algorithms used in some of the country's most popular apps, in
The study, which was recently published in the journal “Scientific Reports,” found that gait patterns among Japanese children aged 6 to 12 vary from those in other developed countries. Age related variations in lower limb movements while walking were studied by scientists from Nagoya University in Japan. For Japanese children in the 11-12 year age group, the number of steps performed each minute was higher than those in the 6-8 year age group.
In this article, we discuss 10 cheap oil stocks to buy today. If you want to skip our detailed analysis of these stocks, go directly to 5 Cheap Oil Stocks to Buy Today. With WTI crude oil prices topping $120 per barrel as recently as mid-June, concerns over rising interest rates and a potential U.S. […]
Kazakhstan is expected to sell some of its crude oil through Azerbaijan's biggest oil pipeline from September, as the nation seeks alternatives to a route Russia threatened to shut, three sources familiar with the matter said. For 20 years, they have been shipped through the CPC pipeline to Russia's Black Sea port of Novorossiisk, which provides access to the global market. In July a Russian court threatened to shut the CPC, prompting the Kazakh government and major foreign producers to set up contracts for other outlets as a precaution.
The U.S. Centers For Disease Control and Prevention has relaxed some guidelines around COVID-19, including the quarantine recommendation for people who have been exposed. Officials say the new guidelines are meant to educate people on how to stay safe without causing much disruption to life, school and work.
Analysts at Goldman Sachs said commodity markets were behaving irrationally, and warned of "unsustainable prices." Prices and inventories are falling, while demand is beating expectations and supply is disappointing, they said in a note late Thursday. Normally, a combination of higher demand and lower supply would make prices rise. The bank lowered its forecast for Brent prices earlier this week. It now predicts $125 a barrel in three months' time and $120 a barrel in 12 months. Goldman Sachs pr
Pfizer (PFE) offers to buy Global Blood Therapeutics (GBT) for $5.4 billion in cash. J&J (JNJ) to discontinue selling talc-based baby powder globally from 2023.
The FTSE 100 pharmaceutical giant's share price suffered its biggest drop since 1998 on Thursday.
The FDA pointed to deficiencies in cleaning and maintenance of equipment to prevent contamination of drug product and also recommended the company review its quality control process, Emergent said. Earlier in August, Emergent had said the FDA had last inspected its facility at Camden in February and was waiting for the agency's feedback.
U.S. manufacturing would make certain vehicle models eligible for a tax credit under the Inflation Reduction Act, a $430 billion bill focused on lowering healthcare costs, promoting clean energy and increasing corporate taxes. Demand for electric vehicles has surged as countries worldwide chase cleaner transport options and seek to achieve net-zero carbon emissions targets to tackle climate change. Production of the Ocean sports utility vehicle (SUV) is slated to begin this November at contract manufacturer Magna International's Austrian unit.
The pharma giant hit back at allegations that the use of Zantac, known chemically as ranitidine, increases the risk of cancer.
Karuna Therapeutics (KRTX) is progressing well with its pipeline development. KRTX's lead candidate meets late-stage study goals as a potential treatment for adults with schizophrenia.
The U.S. climate bill, along with a parallel initiative in Europe, could reshape global energy. Plug Power, Sunrun, and other companies could make the most of the new opportunities in renewables.
(Bloomberg) -- Mexico — which imports nearly all of the natural gas it burns — has laid out a somewhat surprising mission: to become one of the world’s top exporters of the fuel, and fast.Most Read from BloombergAuthor Salman Rushdie Attacked on Lecture Stage in New YorkThe Fed’s Damage to the Housing Market May Last YearsStriking Drop in Stress Hormone Predicts Long Covid in StudyTrump Calls for Release of Warrant Documents Used in SearchPutin’s War Sends Russian Economy Back to 2018 in Single
Demand remains strong for automakers, with supply constraints preventing inventory buildup and supporting strong pricing.
Friends up north and across Tampa Bay snickered when Brian Lafferty revealed where he’d bought a new home. His 30-year-old daughter in Boston called to express concern. Even his ex-wife asked him about it. “Without exception, every person I’ve told I bought a house in The Villages has asked the same thing,” Lafferty said. “‘Isn’t that the STD capital of the United States?’” The Villages, a ...
Merck (NYSE: MRK) is best known for the top-selling cancer drug in the world, Keytruda, which has produced a staggering $10.1 billion in sales through the first half of this year. Keytruda comprised only 33% of the drugmaker's $30.5 billion in total first-half sales. Merck has a pipeline of more than 100 projects under clinical development, which should give it enough firepower to grow revenue and profits with new product launches.
Anne Heche remains in critical condition as police investigate her for a felony DUI.